Uncategorized
Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of an article concerning the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal Drug Discovery Today. The published article, “Pharmacotherapy for Metabolic and Cellular Stress in Degenerative Retinal Diseases,” can be accessed at: https